Maximizing the Potential of Biomanufacturing Cell Lines
|
|
- Gary Palmer
- 5 years ago
- Views:
Transcription
1 Maximizing the Potential of Biomanufacturing Cell Lines
2 Contents Introduction... 3 CHO cells The key trends... 3 The increasing popularity... 3 The biological context... 4 Batch size/price... 4 Novel antibody based therapeutics... 5 Outsourcing approaches... 5 The alternatives to CHO cells... 6 Optimizing CHO cells The key trends... 6 Genome engineering... 6 Methods for improving the GS system... 6 The genome engineering technologies... 7 CRISPR/Cas9 system... 7 recombinant Adeno Associated Virus (raav)... 8 Zinc Finger Nucleases (ZFNs)... 8 Overcoming the challenges in genome engineering... 8 Conclusion... 9 References... 9
3 Introduction The first recombinant protein licensed for use by the United States Food and Drug Administration (US FDA) was human insulin in 1982 (1) ( This was closely followed by tissue plasminogen activator (tpa), the first complex glycosylated protein generated in mammalian cells to be licensed for therapeutic use in Since then, this area of biology has rapidly expanded in the clinic, with an average of 15 new entities being approved by the US FDA every year between 2006 and 2011 for the manufacturing of complex glycoproteins. Although protein yield achieved using CHO cells has increased approximately 100 fold over the years (3), the advances in cell line technology are still limited by the biology of the CHO cell. To increase the potential of the host system, fundamental improvements to the CHO cell line are needed, which is where we believe gene editing can offer a significant step change in biopharmaceutical manufacturing. As the pharmaceutical industry moves towards an ever more fragmented market due to the establishment of personalized medicine, smaller manufacturing runs need to become economically viable. Equally, as therapeutics based around novel protein architecture are developed that are not efficiently produced in current systems, modification of these systems are required to maximise the benefits derived from these exciting new therapies. CHO cells The key trends The increasing popularity The natural characteristics and adaptability of CHO cells have contributed to their popularity Although many systems have been developed to generate biologics over the past 25 years, prokaryotic systems are still primarily used for simple proteins that do not require complex glycosaccharides for their efficacy or stability, and for biologics that need these complex post translational modifications, a mammalian host is needed. CHO cells have recently become the predominant expression system. More recently the safety implications of using animal derived products in the culturing of production cells has led to a preference for cells that are grown in serum free conditions in chemically defined media. Concomitantly, the manufacturing advantage conferred by using cells that can grow at high density in suspension culture has led to a preference in the industry for these cells. The natural characteristics of CHO cells have contributed to their popularity. Amongst others, they: Are relatively easily adaptable to suspension growth in animal component free, chemically defined media, Express and secrete recombinant protein (including antibodies) at relatively high levels and; Provide a human like glycosylation profile. The glycosylation profile is particularly important, preventing the activation of an immune response which can lead to unwanted side effects or the rapid clearance of the drug. In comparison, murine cells for example can induce immunogenic effects through the incorporation of an alpha gal
4 residue (4). Once stably transfected with a vector expressing recombinant protein they generate a heterogeneous population of cells, some of which are expressing high levels of the protein of interest through a combination of integration sites and the ability of CHO cells to amplify regions of genomic DNA. The biological context Advances in cell line technologies are significant, but are still limited by the natural biology of the CHO cell Extensive optimization of culture media and feeding strategies are such that expression levels have increased approximately 100 fold over the initial capabilities. In combination, there have been some alterations to the CHO cells themselves to decrease the time taken to identify the highest expressing clones through the development of metabolic selection systems. These modifications have focussed on selecting those cells which have integrated the expression cassette into sites leading to high expression of recombinant product. Initially this was achieved through the use of the Methotrexate/Dihydrofolate Reductase (MTX/DHFR) system, and then more recently the use of the Methionine Sulphoximine/Glutamine Synthetase (MSX/GS) system. The GS selection system is more stringent than DHFR, leading to reduced timelines to identify high expressing clones (5). However, these advances in cell line technology are still limited by the natural biology of the CHO cell. A selection system can only identify those clones naturally expressing higher levels of protein, and media optimization can only ensure that those clones selected are in the best possible health to produce maximal amounts of protein. To increase the potential of the host system, something more fundamental needs to be improved. Batch size/price It is a valid question to ask whether further advancement is necessary. After all, titres are higher than ever and the time to isolate the production clone is now measured in weeks instead of months or years. Despite this, treatment courses of biotherapeutics are more than twenty times more expensive than small molecule therapeutics (6) ( rch/opportunities for biosimilardevelopment). The CHO expression system is being pushed to its limits as manufacturers drive to make smaller batches economically viable to keep pace with the development of ever more personalized approaches to medicine. Figure 1 Patients are stratified into ever smaller groups as mechanisms of disease progression are linked to individual genotypes, leading to improved therapeutic outcomes for different groups of patients. The same economic argument above can be applied to orphan diseases, with clear benefits to sufferers of these relatively rare conditions.
5 Novel antibody based therapeutics There is an increasing shift towards novel classes of antibody based therapeutics despite setbacks The production of monoclonal antibodies in CHO cells has been the focus of many recent therapies, and the expression of these therapeutics at multi g/l levels is becoming the industry norm. However, even with the increased potency afforded by the new technologies, expression levels are often not high enough to make the production of the active protein economically viable. Figure 2 There is an increasing trend towards novel classes of antibody based therapeutics Existing therapies could also benefit from improving the manufacturing platform. The regulatory acceptance of biosimilars and the large potential markets produced as patents of successful drugs expire have led to a dramatic expansion in companies entering this field. As the current estimated cost of a biosimilar is approximately 50% of the cost of the originator product, potential savings in manufacturing costs are attractive to companies in this field. When producing a biosimilar, similarity of post translational modifications to the originator product is one of the most challenging aspects to address. Currently this is achieved through process modification, but control over aspects such as glycosylation would be a beneficial feature of a production platform. Outsourcing approaches Outsourcing is becoming increasingly popular in the industry with trends towards decreased production scales and increased flexibility While some companies have stated they will keep manufacturing of complex products in house (7) ( Processing/Novartisto keep complex biologics manufacturing inhouse), there is a trend in the industry towards outsourcing manufacturing (8) ( d Articles/ Biopharmaceutical Outsourcing Continues to Expand/). This has led to the emergence of many Contract Manufacturing Organisations (CMOs) with expertise in biologics manufacturing who can fill this need. These companies require efficient use of flexible facilities in order to maximize the utilisation of existing capacity. Multiple smaller bioreactors are now the norm in new facilities to meet market need instead of the large legacy plants containing tens of thousands of litres of capacity. This has also been enabled by the increased adoption of Single Use Bioreactors (SUBs) instead of the investment required to establish large stainless steel bioreactors. The same logic holds for small biotech companies wishing to keep manufacturing in house. The natural extension of this is a trend towards decreased production scales in the industry (9). If cell lines are capable of generating high yielding clones in order for the required amount of protein to be produced at decreased scale, this would fit with the movement towards smaller scale production. Similarly, decreasing the run times of
6 bioreactor batches would increase the flexibility and capacity of existing plants. It is therefore clear that improved production systems leading to increased manufacturing efficiency or control over post translational modifications is attractive to a variety of manufacturers with differing priorities. The alternatives to CHO cells There are a number of concerns that limit uptake of other novel systems To achieve this, the existing options are to alter the CHO cell platform to allow improved expression, or to change systems altogether for one that has an improved basal capacity. There are a number of different available systems, each with their own characteristics. For example plant cells scale easily and produce high titres, while insect cells have also shown high titres. However, there are a number of concerns that limit uptake of novel systems. From a practical perspective, these systems are competing with an extensive history of production of safe therapeutics, so there are concerns over nonmammalian glycosylation moieties. There is similarly a large body of experience of manufacturing using CHO cells. This means that the system is incredibly well characterized, with a known safety profile and well established processes to ensure product quality and consistency between batches. There is therefore a strong case for the industry not to move away from CHO cells but instead fundamentally improve this existing system. There are also many more scientists trained in handling CHO cells than any other expression system, so a change in system would require significant time and resource investment. Optimizing CHO cells The key trends Genome engineering CHO cells are becoming the system of choice with genome engineering allowing almost any characteristic to be altered At Horizon, we are of the opinion that there is a great opportunity to revolutionise the current CHO platform by altering the genome, and we have begun an extensive program to achieve this. This avenue of research could have significant implications for the future of bioprocessing. The GS system is the current industry standard selection system Given the correct targets, the ability to engineer the genome to improve the CHO cell expression system has almost limitless potential. The GS system is the current industry standard selection system and in order to encourage industry uptake and innovation, access to these cells is becoming easier through changes to the licensing paradigm. These cells will then be targeted through further engineering to remove the need for a completely alternative system. Methods for improving the GS system Genome engineering is enabling specific panels of cell lines to overcome particular challenges In order to improve on the GS system, a number of different approaches can be taken, with a number of different steps that could benefit from intervention. Potential modifications can include:
7 Whole gene knockouts, Whole gene knock ins and; Individual point mutations on target genes. with all of the above affecting the activity of target enzymes or substrates. Similarly, multiplexing many different engineering events within one line in a logical way will have synergistic effects on the target phenotype. recombinant Adeno Associated Virus (raav) and; Zinc Finger Nucleases (ZFNs) CRISPR/Cas9 system Genome engineering is now more accessible than ever before with CRISPR/Cas9 In the future, it will even be possible to introduce entire new molecular pathways For example, one could reasonably anticipate that manipulating both transcription and translation would have a multiplicative effect on specific productivity. Alternatively regulation of product quality could be finetuned by controlling transit through the ER as well as careful modification of chaperone proteins. In the future, it will even be possible to introduce entire new molecular pathways. Trait stacking these improvements onto an existing cutting edge line will encourage broad uptake through the industry. By encouraging industry wide uptake of these cells through licensing and performance, they will become a platform technology leading to further improvements through innovation and optimization within different aspects of process development. Furthermore, innovation through engineering these high performance cells for specific applications will lead to a panel of different cell lines, each optimized to overcome particular challenges. The genome engineering technologies Genome editing technologies are available in order to begin to mine the potential of cell line engineering, including: Figure 3 The excitement that has followed the discovery of the CRISPR/Cas9 system (13) has led to a surge in interest in engineering technologies This system has much potential in improving the stacking of engineered modifications, and has already been used to multiplex engineering events (14). Indeed, due to its relatively recent discovery it is still rapidly evolving, with improvements being made to the specificity and efficiency of this exciting new technology, which is making genome engineering more accessible than ever before. This has also been enabled through the sequencing of the CHO genome allowing efficient targeting vectors to be designed. CRISPR is used to rapidly screen hundreds of potential targets in order to identify those with significant effects, and to rapidly test multiplexed edits for synergistic effects It must be stressed that at this stage, the Intellectual Property surrounding CRISPR engineering has yet to be resolved, so while the technology has much potential at the current time, its use is restricted to Research and Development. CRISPR/Cas9 system,
8 recombinant Adeno Associated Virus (raav) Although an established technology it can be time consuming specificity concerns (16). Aside from this, access to ZFNs are cost prohibitive to the majority of companies for use in biomanufacturing. Figure 5 ZFNs, care must be taken to avoid unwanted mutations leading to unintended consequences. Figure 4 raav technology Induction of homologous recombination can be achieved. As the nature of raav means that only one allele can be targeted at a time, the process of introducing multiple events can be time consuming. To overcome this, CRISPR is used to rapidly screen hundreds of potential targets in order to identify those with significant effects, and to rapidly test multiplexed edits for synergistic effects. Following target validation, raav can then be used to generate cell lines that can be used in commercial manufacturing. Zinc Finger Nucleases (ZFNs) Lower efficiencies and specificity concerns currently limits its popularity Zinc Finger Nucleases (ZFNs) work on similar principles to the CRISPR/Cas9 system but have lower efficiencies than CRISPR (15) ( Articles/ Genome Editing with CRISPRs TALENs and ZFNs/) as well as Another area that could also have a large impact on the manufacture of biotherapeutics is in antibody engineering. It is becoming apparent that substitutions of only a few amino acids in the antibody sequence can have a large impact not only on potency, but also on expression and aggregation. Similarly, modification of signal peptides can have a marked increase in the levels of secreted protein. While a full discussion on the potential of this area is beyond the scope of this article, combining optimization of the cell line with co developed expression vectors could have a significant impact on the field in the future. Overcoming the challenges in genome engineering Increased understanding of CHO biology through interpretation of the available omics information is enabling the industry to identify the best targets While the potential of cell line engineering is almost endless, the practicalities are currently limiting. Not only do the best phenotypes need to be identified, but the correct targets then need to be established. This has recently been enabled by the increase in the availability of omics data improving our
9 understanding of CHO biology (10 12). There is still much to be done in order to generate a better understanding of the implications of this new information. Mathematical modelling is rapidly evolving, which will have a positive effect on the ability to predict the impact of a particular modification, but investment in bioinformatics is needed to keep pace with the ambitions of the industry. Due to the ability of a CHO cell to adapt to different pressures, many different proteins in one cell will need to be modified before a strong effect is seen. For example, the complex nature of the metabolic network means that there is a lot of redundancy in the system, and modification of many different aspects may need to occur to achieve the desired result. Conclusion In conclusion, at Horizon, we believe that cell line engineering has great potential to improve existing CHO cell expression systems in a number of ways beyond what is currently available. This is not a simple enterprise, and not without its risks, but the reward could be the ability to produce biotherapeutics cheaply enough to make not only existing therapies more affordable, but allow small production runs to allow the possibility of personalized medicine to become a reality. References 1. A History of Firsts. 2. Lai T, Yang Y, Ng S. Advances in Mammalian Cell Line Development Technologies for Recombinant Protein Production. Pharmaceuticals. Multidisciplinary Digital Publishing Institute; 2013;6(5): Hacker DL, Nallet S, Wurm FM. Recombinant protein production yields from mammalian cells: past, present, and future Figure 6 Horizon s GS / cell platform is the foundation from which it is launching the revolution for the bioprocessing industry. We are now at the stage when increased understanding of CHO biology through interpretation of the available omics information allows us to identify the best targets. Equally, once the correct targets and modifications have been identified, the ability to introduce these to the cells is limitless. 4. van Beers MMC, Bardor M. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnology Journal. WILEY VCH Verlag; 2012;7(12): Fan L, Kadura I, Krebs LE, Hatfield CC, Shaw MM, Frye CC. Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells. Biotechnology and Bioengineering. Wiley Subscription Services, Inc., A Wiley Company; 2011;109(4): Opportunities for biosimilar development. 7. Stanton D. Novartis to keep complex biologics manufacturing in house
10 8. Langer E. Biopharmaceutical Outsourcing Continues to Expand. Pharmaceutical Outsourcing. 2014Jan Jagschies G. Where is Biopharmaceutical Manufacturing Heading? BioPharm International Meuris L, Santens F, Elson G, Festjens N. GlycoDelete engineering of mammalian cells simplifies N glycosylation of recombinant proteins. Nature Biotechnology. Nature Publishing Group; 2014;32(5): Brinkrolf K, Rupp O, Laux H, Kollin F, Ernst W, Linke B, et al Chinese hamster genome sequenced from sorted chromosomes. Nature Biotechnology. Nature Publishing Group; 2013;31(8): Lewis NE, Liu X, Li Y, Nagarajan H, Yerganian G, O'Brien E, et al Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome. Nature Biotechnology. Nature Publishing Group; 2013;31(8): Kildegaard HF, Baycin Hizal D, Lewis NE, Betenbaugh MJ. The emerging CHO systems biology era: harnessing the omics revolution for biotechnology. Current Opinion in Biotechnology. 2013;24(6): Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nature Methods. Nature Publishing Group; 2013;10(10): Grav LM, Lee JS, Gerling S, Kallehauge TB, Hansen AH, Kol S, et al One step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. Biotechnology Journal. WILEY VCH Verlag; 2015;:n/a. 15. Perkel J. Genome Editing with CRISPRs, TALENs and ZFNs Pattanayak V, Ramirez CL, Joung JK, Liu DR. Revealing off target cleavage specificities of zinc finger nucleases by in vitro selection. Nature Methods
Course Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationUpstream mammalian cell processing challenges and prospects
BioProcess International Berlin, April 11-14, 2005 Upstream mammalian cell processing challenges and prospects John Birch Lonza Significance of Mammalian Cell Processes Commercial significance of biopharmaceutical
More informationOpportunities for Accelerating Cell Line Development and Beyond
Opportunities for Accelerating Cell Line Development and Beyond European CM&C Strategy Forum May 24, 2017 Christopher Frye, Ph.D. Research Advisor & Group Leader Bioprocess R&D Presentation Outline CM&C
More informationFuture Perspectives of Antibody Manufacturing
BioProduction 2005 Amsterdam Future Perspectives of Antibody Manufacturing John Birch Lonza Biologics Monoclonal Antibodies A Success Story Fastest growing segment of the pharmaceutical market Sales forecast
More informationUnit 2: Metabolism and Survival Sub-Topic (2.7) Genetic Control of Metabolism (2.8) Ethical considerations in the use of microorganisms
Unit 2: Metabolism and Survival Sub-Topic (2.7) Genetic Control of Metabolism (2.8) Ethical considerations in the use of microorganisms Duncanrig Secondary JHM&MHC 2015 Page 1 of 18 On completion of this
More informationImage adapted from: National Human Genome Research Institute
Jargon buster Image 1: The structure of DNA A double helix with base pairing 1 Image adapted from: National Human Genome Research Institute Allele An allele is one of two or more versions of a gene. An
More informationThis presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
More informationPlant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES
Plant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES PLANT MADE BIOPHARMACEUTICALS: OUR ASSET, YOUR ADVANTAGE We at Greenovation work to advance the development of new treatments
More informationPlant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES
Plant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES BryoTechnology: enables delivery of a wide range of products customized according to the individual needs of our clients 02
More informationAPPROACHES TO IMPROVING THE PERFORMANCE OF MAMMALIAN CELL CULTURES FOR PROTEIN PRODUCTION
BioLOGIC USA BOSTON, 20 th OCTOBER 2004 APPROACHES TO IMPROVING THE PERFORMANCE OF MAMMALIAN CELL CULTURES FOR PROTEIN PRODUCTION Dr Robert Gay Lonza Biologics 2004 The Challenge of the MAb Market Global
More informationRECENT IMPROVEMENTS TO LONZA S GLUTAMINE SYNTHETASE (GS) GENE EXPRESSION SYSTEM. Dr Robert Gay
RECENT IMPROVEMENTS TO LONZA S GLUTAMINE SYNTHETASE (GS) GENE EXPRESSION SYSTEM Dr Robert Gay Lonza Biologics plc, 2004 The Challenge of the MAb Market Global market for Monoclonal Antibody Therapeutics
More informationPharmacogenetics: A SNPshot of the Future. Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001
Pharmacogenetics: A SNPshot of the Future Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001 1 I. What is pharmacogenetics? It is the study of how genetic variation affects drug response
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationFollowing text taken from Suresh Kumar. Bioinformatics Web - Comprehensive educational resource on Bioinformatics. 6th May.2005
Bioinformatics is the recording, annotation, storage, analysis, and searching/retrieval of nucleic acid sequence (genes and RNAs), protein sequence and structural information. This includes databases of
More informationGenome Editing Inventive Energy
Genome Editing Inventive Energy Top 10 Patent Classes Genome Editing Inventive Energy JUNE 2018 Crafitti Consulting Pvt Ltd www.crafitti.com 1 GENOME EDITING INVENTIVE ENERGY 2018 INTERNATIONAL PATENT
More informationWhat do physicians expect from a new drug?
What do physicians expect from a new drug? New drug Novel activity Efficacy Safety Affordable cost Approval of new biologic drugs Is consistently increasing New Biotech Drug and Vaccine Approvals/ New
More informationEvolving of Biological Product Expression Systems with Host Cell Engineering
Evolving of Biological Product Expression Systems with ost Cell Engineering Lianchun Fan Bristol-Myers Squibb CMC Strategy Forum Jan. 23rd, 2017 Outline Choice of expression systems New technologies and
More informationGenetics Faculty of Agriculture and Veterinary Medicine. Instructor: Dr. Jihad Abdallah Topic 16: Biotechnology
Genetics 10201232 Faculty of Agriculture and Veterinary Medicine Instructor: Dr. Jihad Abdallah Topic 16: Biotechnology 1 Biotechnology is defined as the technology that involves the use of living organisms
More informationTrends in capacity utilization for therapeutic monoclonal antibody production
[mabs 1:2, 151-156; March/April 2009]; 2009 Landes Bioscience Report Trends in capacity utilization for therapeutic monoclonal antibody production Eric S. Langer President and Managing Partner; BioPlan
More informationIncorporating SeqStudio Genetic Analyzer and Sanger sequencing into genome editing workflows
Incorporating SeqStudio Genetic Analyzer and Sanger sequencing into genome editing workflows Stephen Jackson, Ph.D 27 May 2017 The world leader in serving science Key Applications for Genome Editing Research
More informationRecombinant protein production in Eukaryotic cells. Dr. W. McLaughlin BC35C
Recombinant protein production in Eukaryotic cells Dr. W. McLaughlin BC35C Recombinant protein production in Eukaryotic cells! rhuman protein must be identical to the natural protein! Prokaryotes are generally
More informationWelcome to all Delegates Biotechnology for Pharmaceutical and Health Classification of Biotechnology Conventional Is a technique that makes use of living organism for specific purpose eg: bread/cheese
More informationThe era of biological medicines
Chapter 1 The era of biological medicines Since their first use in the 1980s, biological medicines (including biosimilar medicines) have grown to become an indispensable tool in modern medicine. Worldwide,
More informationTHE BENEFITS AND USES OF MICROBES
MODULE 4 MICROBES AND MICROBIAL BIOTECHNOLOGY U N I T 2 THE BENEFITS AND USES OF MICROBES A. MICROBIAL BIOTECHNOLOGY 1 Read What is biotechnology? and decide which of the words below can be used instead
More informationPotelligent CHOK1SV. How It Works. Potelligent CHOK1SV
Potelligent CHOK1SV Potelligent CHOK1SV Potelligent CHOK1SV How It Works A new host cell line for the production of recombinant antibodies has been developed through close collaboration between Lonza and
More informationCRISPR/Cas9 Gene Editing Tools
CRISPR/Cas9 Gene Editing Tools - Guide-it Products for Successful CRISPR/Cas9 Gene Editing - Why choose Guide-it products? Optimized methods designed for speed and ease of use Complete kits that don t
More informationCRISPR/Cas9 Gene Editing Tools
CRISPR/Cas9 Gene Editing Tools - Separations Simply Spectacular INDELS Identify indels Determine if one or both copies of your gene have indels The Guide-it Genotype Confirmation Kit: Simple detection
More informationSynthetic Biology. Sustainable Energy. Therapeutics Industrial Enzymes. Agriculture. Accelerating Discoveries, Expanding Possibilities. Design.
Synthetic Biology Accelerating Discoveries, Expanding Possibilities Sustainable Energy Therapeutics Industrial Enzymes Agriculture Design Build Generate Solutions to Advance Synthetic Biology Research
More information- OMICS IN PERSONALISED MEDICINE
SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary
More informationCellular Assays. A Strategic Market Analysis. Sample Slides
A Strategic Market Analysis Sample Slides 2002 For information contact: Frontline Strategic Consulting, Inc. 1065 E. Hillsdale Blvd, Suite 403, Foster City, CA 94404 650-525-1500 x125, x135 or x145 info@frontlinesmc.com
More informationCellca Technology Platform
Cellca Technology Platform Custom Cell Line & Process Development April 2018 Overview: Cellca Technology Platform Cellca CMO/Client Cell Line Development Process Development Process Transfer GMP Production
More informationGenome Editing Technology - Principle -
Effective Date: 31.10.2017 Doc ID: 20290213 Version: 1.0 Status: Approved Planned Effective Date: 31-Oct-2017 00:00 CET (Server Date) Genome Editing Technology - Principle - Rationale Genome editing is
More informationSartorius Stedim Cellca. Custom Cell Line & Process Development for Pharmaceutical Purposes
Sartorius Stedim Cellca Custom Cell Line & Process Development for Pharmaceutical Purposes May 2017 Overview of Contents 1 2 3 Cellca History Overview: Cellca Technology Platform Products & Services 4
More informationChapter 9. Biotechnology and DNA Technology
Chapter 9 Biotechnology and DNA Technology SLOs Compare and contrast biotechnology, recombinant DNA technology, and genetic engineering. Identify the roles of a clone and a vector in making recombined
More informationThe Advent of Subsequent Entry Biologics: Biosimilars Canada. The Advent of Subsequent Entry Biologics. Biosimilars in Canada
The Advent of Subsequent Entry Biologics: Biosimilars Canada The Advent of Subsequent Entry Biologics Biosimilars in Canada Spring 2014 Author: Patrick J. Mott, MSc. Editors Allison Hillier BA, MA Heather
More informationGenetic Characterization of Production Cell Lines
Genetic Characterization of Production Cell Lines Luhong He and Christopher Frye 2017 CMC Strategy Forum Outlines Overview Genetic characterization strategy and case studies Transgene characterization
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationThe use of GMO Technology at Pfizer Ireland. Neysi Ibarra, PhD Senior Manager, Process Development
The use of GMO Technology at Pfizer Ireland Neysi Ibarra, PhD Senior Manager, Process Development Presentation Outline The use of cell culture in the biotechnology industry The complexity of (recombinant)
More informationKupers Luc IMI webinar
Biomanufacturing 2020 (biomfg2020): Development of Innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes Kupers
More informationTargeted complete next generation sequencing and quality control of transgenes and integration sites in CHO cell line development
Targeted Locus Amplification Technology Targeted complete next generation sequencing and quality control of transgenes and integration sites in CHO cell line development Cergentis B.V. Yalelaan 62 3584
More informationNew Plant Breeding Technologies
New Plant Breeding Technologies Ricarda A. Steinbrecher, PhD EcoNexus / ENSSER Berlin, 07 May 2015 r.steinbrecher@econexus.info distributed by EuropaBio What are the NPBTs? *RNAi *Epigenetic alterations
More informationBart Williams, PhD Van Andel Research Center
A History of Genome Editing in the Laboratory Implications for Translational Applications Bart Williams, PhD Van Andel Research Center Introduction by Matthew Denenberg, MD DeVos Childrens Hospital Disclosures:
More informationGenetic Engineering in Agriculture
Details Utah State University Engineering in This is a project resulting from the Engineering Workshop for Teachers to provide teaching materials for genetic engineering topics. Please direct any feedback
More informationGenetics Lecture 21 Recombinant DNA
Genetics Lecture 21 Recombinant DNA Recombinant DNA In 1971, a paper published by Kathleen Danna and Daniel Nathans marked the beginning of the recombinant DNA era. The paper described the isolation of
More informationTHE CRISPR-CAS9 DISPUTE
WHO OWNS THE INTELLECTUAL PROPERTY? THE CRISPR-CAS9 DISPUTE UTRF Tech Talks Dr. Lakita Cavin February 23, 2017 WHAT IS CRISPR-Cas9 Clustered Regularly-Interspaced Short Palindromic Repeats/CRISPR associated
More informationCalendar. The Clear Solution to Reach the Global Biopharma Audience. INTERNATIONAL
The Clear Solution to Reach the Global Biopharma Audience yvdavyd/getty Images & blackred/e+/getty Images 2017 EDITOrial Calendar Editorial Coverage Special Themed Issues January Biopharma Outlook for
More informationCOPYRIGHTED MATERIAL QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS. Rohin Mhatre and Anurag S. Rathore 1.1 INTRODUCTION
1 1.1 INTRODUCTION QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS Rohin Mhatre and Anurag S. Rathore The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should
More informationAdvanced Microbial Protein Expression
Advanced Microbial Protein Expression Partners for Life Advancing tomorrow s medicines w A Biologics and Vaccines CDMO partner for your complete clinical journey Good science, experience and a quality
More informationThe era of biological medicines
Chapter 1 The era of biological medicines Since their first use in the 1980s, biological medicines (including biosimilar medicines) have grown to become an indispensable tool in modern medicine. Worldwide,
More informationPersonalized Human Genome Sequencing
Personalized Human Genome Sequencing Dr. Stefan Platz DABT, Global Head Drug Safety & Metabolism Biomedical research: strengths & limitations of non-animal alternatives 06 December 2016 The Human Genome
More informationCRISPR/Cas9 Genome Editing: Transfection Methods
CRISPR/ Genome Editing: Transfection Methods For over 20 years Mirus Bio has developed and manufactured high performance transfection products and technologies. That expertise is now being applied to the
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationCRISPR/Cas9 engineering and bioinformatics. Leopold Parts 10/05/2018
CRISPR/Cas9 engineering and bioinformatics Leopold Parts 10/05/2018 CRISPR/Cas9 engineering and bioinformatics CRISPR/Cas9 background Genome engineering in olden days: RE and HR DNA break repair as a basic
More informationGenetics and Genomics in Medicine Chapter 9 Questions
Genetics and Genomics in Medicine Chapter 9 Questions Multiple Choice Questions Question 9.1 Which, if any, of the following can be classified as a type of augmentation therapy? a) Treatment using a small
More informationOverview and Summary of NABC 26 New DNA-Editing Approaches: Methods, Applications and Policy for Agriculture
Overview and Summary of NABC 26 New DNA-Editing Approaches: Methods, Applications and Policy for Agriculture OVERVIEW Recently developed technologies zinc finger nucleases (ZFNs), meganucleases (MNs),
More informationChapter 13: Biotechnology
Chapter Review 1. Explain why the brewing of beer is considered to be biotechnology. The United Nations defines biotechnology as any technological application that uses biological system, living organism,
More informationEffectively utilizing Post Translational Modification analysis to fast track process development for Biosimilars
Effectively utilizing Post Translational Modification analysis to fast track process development for Biosimilars Sanjeev Gupta DGM-Advanced Biotech (R&D) Ipca Laboratories Ltd., Mumbai, India March 04,
More informationProtein Sources (Heterologous expression of proteins)
Protein Sources (Heterologous expression of proteins) Adrian Suarez Covarrubias Before starting out - why? what? when? where? Recombinant expression? if so, choice of host: prokaryote? eukaryote? modification
More informationGene Therapy: The Basics. Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University
Gene Therapy: The Basics Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University Definition of gene therapy Gene therapy is the introduction of nucleic acids (e.g. DNA/genes) into somatic
More informationDNA Cloning with Cloning Vectors
Cloning Vectors A M I R A A. T. A L - H O S A R Y L E C T U R E R O F I N F E C T I O U S D I S E A S E S F A C U L T Y O F V E T. M E D I C I N E A S S I U T U N I V E R S I T Y - E G Y P T DNA Cloning
More informationMRC-NIHR National Phenome Centre
MRC-NIHR National Phenome Centre PROFESSOR JEREMY NICHOLSON Director of the MRC-NIHR National Phenome Centre OUR PHILOSOPHY Disease risk at the individual and population level is determined by complex
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationRasha Sayed Salama, MD, PhD, UAE
GaBI Scientific Meetings 10 October 2018, Le Meridien Dubai, United Arab Emirates 2nd MENA Stakeholder Meeting on Regulatory Approval, Clinical Settings, Interchangeability and Pharmacovigilance of Biosimilars
More informationPersonalized CAR-T Immunotherapy Platform
GLP, GMP, and CLIA-Certified Lab Personalized CAR-T Immunotherapy Platform Accelerate your cancer research and drug discovery Platform Overview 1500 Existing Hybridomas and Antibody Engineering Custom
More informationWhat is Biotechnology? Micro 566 Microbial biotechnology Presented by Prof. Nagwa M. Aref
What is Biotechnology? Micro 566 Microbial biotechnology Presented by Prof. Nagwa M. Aref 1.1 Defining Biotechnology Biotechnology- the study and manipulation of living things or their component molecules,
More informationHealthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation
Healthcare Healthcare The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation (CPI)
More informationAdvancing Manufacturing for Advanced Therapies
Advancing Manufacturing for Advanced Therapies Peter Marks, MD, PhD Center For Biologics Evaluation and Research, FDA CASSS Cell & Gene Therapy Symposium July 10, 2018 Overview Cell and gene therapy products
More informationMammalian Expression Platform
Mammalian Expression Platform Partners for Life Advancing tomorrow s medicines w Your CDMO partner for biologics and advanced therapies Good science, experience and a quality driven approach Line/Strain
More informationBiotechnology, Synthetic Biology, and Genetic Circuit Design Module Lesson Plan. 1 day. 1 P age
1 P age Biotechnology, Synthetic Biology, and Genetic Circuit Design Module Lesson Plan 1 day 2 P age Introduction In this single module students will build upon their previous knowledge of basic molecular
More informationRapid selection of high yielding GS-CHO cell lines using the GS expression system in a protein-free, chemically defined, animal component-free process
Rapid selection of high yielding GS-CHO cell lines using the GS expression system in a protein-free, chemically defined, animal component-free process David Mainwaring, Lonza Biologics. Introduction Chemically
More informationPharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA
Pharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA 1 2 ND MENA Regulatory Conference On Bioequivalence, Biowaivers, Bioanalysis, Dissolution & Biosimilars
More informationOverview of Biosimilars: How Do They Differ From Generics? Thomas Felix, MD R&D Policy Global Regulatory Affairs and Safety
Overview of Biosimilars: How Do They Differ From Generics? Thomas Felix, MD R&D Policy Global Regulatory Affairs and Safety 1 Our Dual Role Amgen is a biotechnology company developing both innovative biologic
More informationInvestigating Critical Challenges in the Gene Therapy Field
Investigating Critical Challenges in the Gene Therapy Field Mapping out the Landscape & Discussing Future Strategies Sander van Deventer Managing Partner Forbion Capital Partners CSO and General Manager
More informationRegulatory Consideration for Biotechnology Products: Clonality of the Production Cell Bank
Regulatory Consideration for Biotechnology Products: Clonality of the Production Cell Bank Rashmi Rawat, Ph.D. Office of Biotechnology Products OPQ/CDER/FDA Informa Life Sciences Annual Cell Line Development
More informationApplying Affimers. Dr Amanda Nicholl at Avacta Life Sciences. Improving Antibody PK Assay Development
Improving Pharmacokinetic Assays in a Regulatory Bioanalysis Setting Applying Affimers With an increasing number of antibody-based therapeutics entering the clinic, the need for validated anti-idiotypic
More informationPatent Analytics Research Report
SANGAMO THERAPEUTICS Patent Analytics Research Report May 2018 CRISPR IP assets Copy for IPStudies Corporate access Executive summary This research report specifically reviews the IP strategy and positioning
More informationPersonalised Medicine Regulatory Issues
Personalised Medicine Regulatory Issues INFRAFRONTIER / IMPC Stakeholder Meeting Presented by Marisa Papaluca on 14 November 2017 Senior Scientific Advisor, Scientific Committees Regulatory Science Strategy
More informationIndia as an Outsourcing Frontier in Biotechnology
1 India as an Outsourcing Frontier in Biotechnology K.V. Subramaniam President & CEO 3 rd Annual Biotech Supply Chain Academy Conference San Francisco Oct 26, 2010 Biotechnology Industry Issues Long gestation
More informationGenes to Proteins to Antibodies
Genes to Proteins to Antibodies About Us Fusion Antibodies is a CRO established in 2001 as a spin-out from Queen s University Belfast. The company building is situated in a charming area of Springbank
More informationContract Manufacturing of Biosimilars
Contract Manufacturing of Biosimilars Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. IBC Life Science s Biopharmaceutical Development and Production Huntington Beach, CA February
More informationChapter 8 Healthcare Biotechnology
Chapter 8 Healthcare Biotechnology Outline: 8.1 Introduction 8.2 Biopharming 8.3 Models of Human Disease 8.4 Detecting and Diagnosing Human Disease 8.5 Monoclonal Antibodies 8.6 Gene Therapy 8.7 Tissue
More informationSangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy
April 24, 2017 Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy RICHMOND, Calif., April 24, 2017 /PRNewswire/ -- Sangamo Therapeutics,
More informationDon Stewart, PhD President and CEO (416)
PlantForm Corporation Don Stewart, PhD President and CEO (416) 452 7242 don.stewart@plantformcorp.com www.plantformcorp.com PlantForm Opportunity Proprietary, plant-based manufacturing of monoclonal antibody
More informationPharma&Biotech. Developability Assessment Platform Reduce Attrition Rates, Improve Clinical Safety and Avoid the Valley of Death
Pharma&Biotech Developability Assessment Platform Reduce Attrition Rates, Improve Clinical Safety and Avoid the Valley of Death The Valley of Death Development risk, safety and high attrition rates remain
More informationBasic Concepts and History of Genetic Engineering. Mitesh Shrestha
Basic Concepts and History of Genetic Engineering Mitesh Shrestha Genetic Engineering AKA gene manipulation, gene cloning, recombinant DNA technology, genetic modification, and the new genetics. A technique
More informationSoil bacteria to produce new antibiotics
Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/soil-bacteria-to-produce-newantibiotics/ Soil bacteria to produce new antibiotics An ever-growing number of genomes of
More informationThe Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives
The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products CDER/FDA CASSS, Applications of
More informationImmunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals
Immunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals Daniel Kramer/Kathleen Beach Need for public-private collaboration 1 All biopharmaceuticals are
More informationPatricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, (732)
Pharmaceutical Technology Patricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, pvanarnum@advanstar.com, (732) 346-3072 Biopharmaceutical Industry in 2012: Optimism on the Rise
More informationFig. 5.1(a) and Fig. 5.1(b), on page 3 of the insert, show some changes that take place in the fermenter over the first 6 days.
1 A batch fermenter is used during the production of beer. Fig. 5.1(a) and Fig. 5.1(b), on page 3 of the insert, show some changes that take place in the fermenter over the first 6 days. (a) (i) Describe
More informationPlantForm Corporation
PlantForm Corporation Annual General Meeting September 21, 2010 Dr. Don Stewart President and CEO +1 (416) 452 7242 don.stewart@plantformcorp.com PlantForm Corporation 2010 www.plantformcorp.com The Opportunity
More informationFusion Antibodies. Genes to Proteins to Antibodies
Fusion Antibodies Genes to Proteins to Antibodies Why Fusion Antibodies? 12 years experience of Antibody drug development Milestoned Payments European based limited company High Quality outcomes for the
More informationCorporate Presentation. March 2018
Corporate Presentation March 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
More informationGenome editing: Principles, Current and Future Uses
enome editing: Principles, urrent and Future Uses Dr ndrew Wood University of Edinburgh alton Institute dvance in enetics onference June 28 th 2017 enome editing defined: a type of genetic engineering
More informationBiotechnology Fifth edition
Biotechnology Fifth edition Biotechnology is the major technology of the twenty-first century yet few people realise how much it impacts on many aspects of human society. The defining aim of this new fifth
More informationBiotechnology. Chapter 20. Biology Eighth Edition Neil Campbell and Jane Reece. PowerPoint Lecture Presentations for
Chapter 20 Biotechnology PowerPoint Lecture Presentations for Biology Eighth Edition Neil Campbell and Jane Reece Lectures by Chris Romero, updated by Erin Barley with contributions from Joan Sharp Copyright
More informationWe are committed to translating ground-breaking science into genomic therapies that transform patients lives
We are committed to translating ground-breaking science into genomic therapies that transform patients lives Liver-based expression of the human alpha-galactosidase A gene (GLA) in a murine Fabry model
More informationOverview: The DNA Toolbox
Overview: The DNA Toolbox Sequencing of the genomes of more than 7,000 species was under way in 2010 DNA sequencing has depended on advances in technology, starting with making recombinant DNA In recombinant
More informationTransition to Next Gen Downstream Processing to Capitalize on Growth Opportunities in High-Value Low-Volume Biologics
A Virtual Think Tank Executive Summary Transition to Next Gen Downstream Processing to Capitalize on Growth Opportunities in High-Value Low-Volume Biologics By: Unmesh Lal, Program Manager, Transformational
More information10 years of biomanufacturing: Industry maturity shown in the shifts toward process improvement
10 years of biomanufacturing: Industry maturity shown in the shifts toward process improvement Bioprocess International Anne Montgomery ~1500 words, 2 graphs. The biopharmaceutical industry is emerging
More information